Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial

被引：0

作者：

Breedveld, Ferdinand C. ^{[1
]}

Keystone, Edward ^{[2
]}

van der Heijde, Desiree ^{[1
]}

Landewe, Robert ^{[3
]}

Smolen, Josef ^{[4
,5
]}

Guerette, Benoit ^{[6
]}

McIlraith, Melissa ^{[6
]}

Kupper, Hartmut ^{[7
]}

Liu, Shufang ^{[8
]}

Wolfe, Benjamin ^{[8
]}

Kavanaugh, Arthur ^{[9
]}

机构：

[1] Leiden Univ, Med Ctr, Leiden, Netherlands

[2] Univ Toronto, Toronto, ON, Canada

[3] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[4] Med Univ Vienna, Vienna, Austria

[5] Hietzing Hosp, Vienna, Austria

[6] Abbott, Rungis, France

[7] Abbott GmbH & Co KG, Ludwigshafen, Germany

[8] Abbott, Abbott Pk, IL USA

[9] Univ Calif San Diego, San Diego, CA 92103 USA

来源：

ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1231

引用

页码：S481 / S481

页数：1

共 50 条

[31] Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Josef S. Smolen
Ronald van Vollenhoven
Arthur Kavanaugh
Vibeke Strand
Jiri Vencovsky
Michael Schiff
Robert Landewé
Boulos Haraoui
Catherine Arendt
Irina Mountian
David Carter
Désirée van der Heijde
Arthritis Research & Therapy, 17
[32] Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Smolen, Josef S.
van Vollenhoven, Ronald
Kavanaugh, Arthur
Strand, Vibeke
Vencovsky, Jiri
Schiff, Michael
Landewe, Robert
Haraoui, Boulos
Arendt, Catherine
Mountian, Irina
Carter, David
van der Heijde, Desire
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[33] Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study
Hirose T.
Saitoh C.
Oikawa I.
Kondo N.
Diabetology International, 2018, 9 (3) : 168 - 178
[34] Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
Arnold, Douglas
Freeman, Leorah
Hartung, Hans-Peter
Montalban, Xavier
Cohen, Jeffrey
Bar-Or, Amit
Steinman, Lawrence
DeLuca, John
Sheffield, James
Cheng, Chun-Yen
Riolo, Jon
Pachai, Chahin
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1050 - 1051
[35] LONG-TERM BENEFITS OF 4-WEEKLY CERTOLIZUMAB PEGOL COMBINATION AND MONOTHERAPY ON HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY
Strand, V
Purcaru, O.
Van Vollenhoven, R.
Choy, E.
Fleischmann, R.
VALUE IN HEALTH, 2012, 15 (07) : A451 - A452
[36] Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Strand, Vibeke
Purcaru, Oana
van Vollenhoven, Ronald F.
Choy, Ernest
Fleischmann, Roy
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S567 - S567
[37] Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension
Keystone, Edward C.
Breedveld, Ferdinand C.
van der Heijde, Desiree
Landewe, Robert
Florentinus, Stefan
Arulmani, Udayasankar
Liu, Shufang
Kupper, Hartmut
Kavanaugh, Arthur
JOURNAL OF RHEUMATOLOGY, 2014, 41 (01) : 5 - 14
[38] Long-Term Safety of Lacosamide as Adjunctive Therapy in Patients with Uncontrolled Partial-Onset Seizures: Results from a Phase III Open-Label Extension Trial
Husain, Aatif
Faught, Raymond Edward
Chung, Steve
Isojarvi, Jouko
McShea, Cindy
Doty, Pamela
NEUROLOGY, 2011, 76 (09) : A291 - A291
[39] Efficacy of long-term (104-week) treatment with apremilast in patients with psoriatic arthritis: Results from a phase III, randomized, controlled trial and open-label extension
Edwards, Christopher
Blanco, Francisco
Crowley, Jeffrey
Hu, Chia Chi
Shah, Kamal
Birbara, Charles
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[40] LONG-TERM (104-WEEK) EFFICACY AND SAFETY OF APREMILAST MONOTHERAPY IN DMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 4)
Bird, P.
Wells, A.
Edwards, C.
Adebajo, A.
Kivitz, A.
Shah, K.
Hu, C.
Aelion, J.
INTERNAL MEDICINE JOURNAL, 2015, 45 : 40 - 40

← 1 2 3 4 5 →